Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 30Pancreatic Neoplasms 10Squamous Cell Carcinoma of Head and Neck 8Rectal Neoplasms 7Lung Neoplasms 7Gliosarcoma 7Glioblastoma 7Colonic Neoplasms 7Carcinoma, Hepatocellular 7Brain Neoplasms 7Esophageal Neoplasms 5Carcinoma, Renal Cell 5Astrocytoma 5Adenocarcinoma of Lung 5Salivary Gland Neoplasms 4Gallbladder Neoplasms 4Carcinoma, Ovarian Epithelial 4Bile Duct Neoplasms 4Adenocarcinoma, Bronchiolo-Alveolar 4Oligodendroglioma 3Esthesioneuroblastoma, Olfactory 3Breast Neoplasms 3Uterine Cervical Neoplasms 2Urinary Bladder Neoplasms 2Tongue Neoplasms 2Stomach Neoplasms 2Pancreatic Intraductal Neoplasms 2Mesothelioma, Malignant 2Medulloblastoma 2Hereditary leiomyomatosis and renal cell cancer 2

Interventions

veliparib 1tipifarnib 1pazopanib 1Mitozytrex 1Mitomycin 1Immunoglobulin G 1Erlotinib Hydrochloride 1Disulfides 1Bevacizumab 1ARQ 197 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Solid Neoplasm × Erlotinib Hydrochloride × Clear all
NCT00085553 2018-05-18

Tipifarnib and Erlotinib Hydrochloride in Treating Patients With Advanced Solid Tumors

National Cancer Institute (NCI)

Phase 1 Completed
29 enrolled

Solid Neoplasm

Data powered by HemOnc (CC BY 4.0) Colophon âš¡